Watch this CME/CE/CNE session anytime On Demand. 

This activity covers the treatment and management of patients with bladder cancer. 

Educational Objectives

  • Critically evaluate the advantages and drawbacks of various CPGs for treating bladder cancer (BC), and apply the most useful and practical recommendations in clinical practice
  • Understand the molecular pathways involved in the development and progression of MIBC and NMIBC, and adopt diagnostic, predictive, and prognostic biomarkers into clinical practice, as they are perfected and become widely available for clinical use
  • Implement tactics for the successful management of irAEs experienced by BC patients treated with ICIs and other immunotherapies, allowing uninterrupted courses of treatment and minimizing diminishment of patients’ QOL


Arjun V. Balar, MD
Director, Genitourinary Medical Oncology Program
Perlmutter Cancer Center at NYU Langone Health
Asst. Professor, Dept. of Medicine, NYU School of Medicine

Educational Audience
This activity is designed to meet the educational needs primarily of urologists and other clinicians involved in the treatment of patients with bladder cancer.

This program expires May 7, 2022. 

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

Purpose: This program would be beneficial for nurses who are involved in the management of patients with bladder cancer. Credits: 1.0 ANCC Contact Hour

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient out­comes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the live virtual event at [email protected]


This activity is provided by Med Learning Group.

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). 

This activity is supported by an educational grant from Bristol Myers Squibb. 

Immunotherapy of Bladder Cancer: Integrating New Biomarkers and Treatment Guidelines into Clinical Practice